Literature DB >> 16137584

Pancreaticoduodenectomy in the presence of superior mesenteric venous obstruction.

Leonidas G Koniaris1, Kevin F Staveley-O'Carroll, Herbert J Zeh, Eduardo Perez, Xiao-ling Jin, Warren R Maley, Gazi Zabari, David L Bartlett, Amit Khanna, Dido Franceschi, Luke O Schoeniger.   

Abstract

The study goal was to determine the technical feasibility and outcomes associated with pancreaticoduodenectomy for periampullary malignancies with near (>80%) or complete (100%) superior mesenteric venous (SMV) obstruction. A retrospective examination of 11 patients with high-grade or complete SMV obstruction who underwent pancreaticoduodenectomy at five academic medical centers is reviewed. Pancreaticoduodenectomy for locally advanced periampullary malignancies causing high-grade or complete SMV obstruction is technically feasible. Operative approaches and outcomes are presented. One 30-day death was observed. Median survival of the cohort is 18 months. Survivals exceeding 2 years post-resection have been observed. In a number of cases, significant palliation of pain and of biliary and duodenal obstruction were achieved. Based on this initial series, pancreaticoduodenectomy in the presence of near or total SMV obstruction is feasible, may result in an R0 resection, and may be beneficial in select patients with a periampullary malignancy. We suggest such an approach be considered particularly following completion of neoadjuvant therapy without systemic progression. Further studies and more long-term follow-up at high-volume centers are required, however, to better determine the indications and potential benefit of such an undertaking.

Entities:  

Mesh:

Year:  2005        PMID: 16137584     DOI: 10.1016/j.gassur.2005.04.005

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  19 in total

1.  Treatment of cancer of the exocrine pancreas.

Authors:  M G Sarr
Journal:  Am J Surg       Date:  1999-11       Impact factor: 2.565

2.  Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma.

Authors:  Y Nukui; V J Picozzi; L W Traverso
Journal:  Am J Surg       Date:  2000-05       Impact factor: 2.565

Review 3.  The quick, no-twist, no-kink portal confluence reconstruction.

Authors:  Leonidas G Koniaris; Luke O Schoeniger; Stephen Kovach; James V Sitzmann
Journal:  J Am Coll Surg       Date:  2003-03       Impact factor: 6.113

4.  Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators.

Authors:  T A Sohn; C J Yeo; J L Cameron; L Koniaris; S Kaushal; R A Abrams; P K Sauter; J Coleman; R H Hruban; K D Lillemoe
Journal:  J Gastrointest Surg       Date:  2000 Nov-Dec       Impact factor: 3.452

5.  Regional resection of cancer of the pancreas: a new surgical approach.

Authors:  J G Fortner
Journal:  Surgery       Date:  1973-02       Impact factor: 3.982

6.  Rapid exposure of the portal and superior mesenteric veins.

Authors:  J L Cameron
Journal:  Surg Gynecol Obstet       Date:  1993-04

7.  Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial.

Authors:  H Snady; H Bruckner; A Cooperman; J Paradiso; L Kiefer
Journal:  Cancer       Date:  2000-07-15       Impact factor: 6.860

8.  Pancreaticoduodenectomy with vascular resection: margin status and survival duration.

Authors:  Jennifer F Tseng; Chandrajit P Raut; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Eddie K Abdalla; Henry F Gomez; Charlotte C Sun; Christopher H Crane; Robert A Wolff; Douglas B Evans
Journal:  J Gastrointest Surg       Date:  2004-12       Impact factor: 3.452

9.  Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas.

Authors:  R R White; H I Hurwitz; M A Morse; C Lee; M S Anscher; E K Paulson; M R Gottfried; J Baillie; M S Branch; P S Jowell; K M McGrath; B M Clary; T N Pappas; D S Tyler
Journal:  Ann Surg Oncol       Date:  2001-12       Impact factor: 5.344

10.  Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.

Authors:  Vincent J Picozzi; Richard A Kozarek; L William Traverso
Journal:  Am J Surg       Date:  2003-05       Impact factor: 2.565

View more
  4 in total

Review 1.  Extended pancreaticoduodenectomy with vascular resection for pancreatic cancer: a systematic review.

Authors:  Terence C Chua; Akshat Saxena
Journal:  J Gastrointest Surg       Date:  2010-04-09       Impact factor: 3.452

Review 2.  Vascular invasion in pancreatic cancer: Imaging modalities, preoperative diagnosis and surgical management.

Authors:  Nicolas C Buchs; Michael Chilcott; Pierre-Alexandre Poletti; Leo H Buhler; Philippe Morel
Journal:  World J Gastroenterol       Date:  2010-02-21       Impact factor: 5.742

3.  Vascular resection in pancreatic cancer surgery: survival determinants.

Authors:  Sascha A Müller; Mark Hartel; Arianeb Mehrabi; Thilo Welsch; David J Martin; Ulf Hinz; Bruno M Schmied; Markus W Büchler
Journal:  J Gastrointest Surg       Date:  2009-01-10       Impact factor: 3.452

4.  Combined pancreaticoduodenectomy and extended right hemicolectomy: outcomes and indications.

Authors:  Eric T Kimchi; Mehrdad Nikfarjam; Niraj J Gusani; Diego M Avella; Kevin F Staveley-O'Carroll
Journal:  HPB (Oxford)       Date:  2009-11       Impact factor: 3.647

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.